Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression
- 8 June 2022
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (648) , eabh1261
Abstract
Tumor evasion of immune destruction is associated with the production of immunosuppressive adenosine in the tumor microenvironment (TME). Anticancer therapies can trigger adenosine triphosphate (ATP) release from tumor cells, causing rapid formation of adenosine by the ectonucleotidases CD39 and CD73, thereafter exacerbating immunosuppression in the TME. The goal of this study was to develop an approach to facilitate cancer therapy–induced immunogenic cell death including ATP release and to limit ATP degradation into adenosine, in order to achieve durable antitumor immune response. Our approach was to construct reactive oxygen species (ROS)–producing nanoparticles that carry an ectonucleotidase inhibitor ARL67156 by electronic interaction and phenylboronic ester. Upon near-infrared irradiation, nanoparticle-produced ROS induced ATP release from MOC1 cancer cells in vitro and triggered the cleavage of phenylboronic ester, facilitating the release of ARL67156 from the nanoparticles. ARL67156 prevented conversion of ATP to adenosine and enhanced anticancer immunity in an MOC1-based coculture model. We tested this approach in mouse tumor models. Nanoparticle-based ROS-responsive drug delivery reprogramed the immunogenic landscape in tumors, eliciting tumor-specific T cell responses and tumor regression, conferring long-term survival in mouse models. We demonstrated that TME reprograming sets the stage for response to anti-programmed cell death protein 1 (PD1) immunotherapy, and the combination resulted in tumor regression in a 4T1 breast cancer mouse model that was resistant to PD1 blockade. Furthermore, our approach also induced immunological effects in patient-derived organotypic tumor spheroid model, suggesting potential translation of our nanoparticle approach for treating human cancers.Keywords
This publication has 78 references indexed in Scilit:
- Regulation of Inflammation by AdenosineFrontiers in Immunology, 2013
- Comparative Analysis of Tumor‐Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral CancerOtolaryngology–Head and Neck Surgery, 2012
- ERK1/2 Regulation of CD44 Modulates Oral Cancer AggressivenessCancer Research, 2012
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer ImmunityCancer Research, 2010
- Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearanceNature, 2009
- Hydrolysis of extracellular ATP and immune suppression: humans versus miceBlood, 2008
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionJournal of Experimental Medicine, 2007
- CD39/NTPDase-1 activity and expression in normal leukocytesThrombosis Research, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006